

2023

Prior Authorization Criteria

Last Updated: 05/16/2023

HPMS Approved Formulary File Submission 00023576 Version Number 14

Actimmune

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis, supporting imaging for osteopetrosis. Antibiotic failure if chronic granulomatous disease
Age Restrictions	Ages approved in FDA labeling/compendia
Prescriber Restrictions	Infectious Disease/Hematology-oncology/Orthopedist/rheumatologist
Coverage Duration	12 months
Other Criteria	Sulfamethoxazole/Trimethoprim and/or itraconazole failure for infections secondary to chronic granulomatous disease. Osteopetrosis must be severe malignant
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Adcirca Tabs

Products Affected

- *tadalafil (pah)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Right Heart catheterization, vasoreactivity test.
Age Restrictions	
Prescriber Restrictions	Pulmonology, Cardiology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Adempas

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	pulmonologist/cardiologist
Coverage Duration	12 months
Other Criteria	For PAH must have tried and failed ambrisentan and tadalafil, CTPH requires failure of bosentan (based on compendial support)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Afinitor

Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/neurology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Aimovig

Products Affected

- AIMOVIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology, Pain Management, Headache Specialist
Coverage Duration	12 months
Other Criteria	Recent failure (in the past 6 months) of two medications FDA indicated for chronic or episodic migraine prophylaxis
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Alecensa

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Approved for ALK+ Non Small Cell Lung Cancer
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

alitretinoin (Panretin)

Products Affected

- PANRETIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Alunbrig

Products Affected

- ALUNBRIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ambrisentan

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, including right heart catheterization, 6 Minute Walk time
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Pulmonologist or cardiologist
Coverage Duration	12 months
Other Criteria	Pulmonary hypertension must be diagnosed by heart catheterization ,Evaluation, EKG, diffusion studies, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral ,Coverage will be based on medical history/status, vasoreactivity tests.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ampyra

Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	History of seizure. Moderate or severe renal impairment (creatinine clearance less than or equal to 50 mL/minute).
Required Medical Information	Diagnosis of multiple sclerosis AND patient is ambulatory (able to walk at least 25 feet) AND patient has walking impairment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial - 3 months. Renewal - 12 months
Other Criteria	For renewal, walking speed has improved from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Apokyn

Products Affected

- *apomorphine hcl subcutaneous*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, previous treatment history.
Age Restrictions	Ages approved in FDA labeling/compendia
Prescriber Restrictions	Neurologist
Coverage Duration	12 months
Other Criteria	Patient must have poorly controlled off time episodes and failed dopamine agonist and COMT inhibitor
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Aptiom

Products Affected

- APTIOM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Failure of carbamazepine and Oxcarbazepine
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Arcalyst

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Coverage will be based on a Diagnosis of CAPS, failure of 1 other treatment used for this condition such as canakinumab, nsaid. Will also be covered for recurrent pericarditis and deficiency of interleukin-1 receptor antagonist.
Age Restrictions	
Prescriber Restrictions	Immunologist, dermatologist, rheumatologist, cardiologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Armodafinil/Modafinil

Products Affected

- *armodafinil*
- *modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Aubagio

Products Affected

- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Failure of Glatopa and Gilenya
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Auvelity

Products Affected

- AUVELITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Psychiatry and Neurology
Coverage Duration	12 months
Other Criteria	Failure of bupropion and failure of aripiprazole in combination with any antidepressant.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Avonex

Products Affected

- AVONEX PEN INTRAMUSCULAR SYRINGE KIT
AUTO-INJECTOR KIT
- AVONEX PREFILLED
INTRAMUSCULAR PREFILLED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Failure of glatiramer
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ayvakit

Products Affected

- AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	hematology/oncology/immunology/allergy
Coverage Duration	12 months or until progression
Other Criteria	Failure of imatinib AND one other tyrosine kinase inhibitor for unresectable or metastatic GIST with a mutation in PDGFRA exon 18 or failure of imatinib and harboring a PDGFRA D842V mutation. Diagnosis of advanced systemic mastocytosis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

aztreonam (Cayston)

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 Months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Balversa

Products Affected

- BALVERSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Urology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Banzel

Products Affected

- *rufinamide*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Benlysta

Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Member receiving other biologic therapy or intravenous cyclophosphamide.
Required Medical Information	FOR SLE Diagnosis of active, autoantibody-positive, systemic lupus erythematosus (SLE), and member currently receiving one or more of the following standard SLE therapies: Corticosteroids, Antimalarials, Non-steroidal anti-inflammatory drugs (NSAIDs), Immunosuppressants. For lupus nephritis must fail tacrolimus and mycophenolate.
Age Restrictions	Greater or equal to 18 years of age
Prescriber Restrictions	Rheumatologist or nephrologist
Coverage Duration	Lifetime
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Berinert

Products Affected

- BERINERT

PA Criteria	Criteria Details
Exclusion Criteria	Must not be taking medications that can exacerbate the frequency and/or severity of hereditary angioedema (HAE) attacks including estrogens and ACE inhibitors.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Besremi

Products Affected

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology Oncology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Betaseron

Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Failure of glatiramer
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Bosulif

Products Affected

- BOSULIF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months or until disease progression
Other Criteria	Requires failure of imatinib for low risk CML based on Sokal or Hasford scores. Can be used first line for Ph+ CML with an intermediate to high risk Sokal or Hasford score
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Braftovi

Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Evidence of BRAF mutation
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progresison
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Briviact

Products Affected

- BRIVIACT ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	failed trial or contraindication or intolerance of Levetiracetam
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Brukinsa

Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	Disease progression on a covalent BTK inhibitor
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/oncology
Coverage Duration	12 months or until progression
Other Criteria	Intolerance to Imbruvica in overlapping indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cabometyx

Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Covered until disease progression.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Calquence

Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or clinical progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Caplyta

Products Affected

- CAPLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	written by neurology/psychiatry
Coverage Duration	12 months
Other Criteria	failure of aripiprazole and risperidone for schizophrenia.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Caprelsa

Products Affected

- CAPRELSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Carbaglu

Products Affected

- *carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

cialis

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	excluded from part D coverage when prescribed for treatment of erectile dysfunction
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Approved for treatment of benign prostatic hyperplasia.
Indications	Some FDA-approved Indications Only.
Off Label Uses	
Part B Prerequisite	No

Cinryze

Products Affected

- CINRYZE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cometriq

Products Affected

- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	combination use with other tyrosine Kinase inhibitors.
Required Medical Information	Diagnosis
Age Restrictions	
Prescriber Restrictions	oncology/hematology
Coverage Duration	6 months or until disease progression
Other Criteria	Covered for Metastatic Thyroid Medullary Cancer
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Copiktra

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Corlanor

Products Affected

- CORLANOR ORAL SOLUTION
- CORLANOR ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of the following: 1. Diagnosis of chronic heart failure with left ventricular ejection fraction less than or equal to 35% AND 2. Patient is in sinus rhythm with resting heart rate greater than or equal to 70 beats per minute AND 3. Patient is on maximally tolerated doses of beta-blockers or has a contraindication to beta-blocker use AND 4. Patient is receiving an ACE inhibitor or ARB or has a contraindication to these agents. Approved for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (with a left ventricular ejection fraction less than or equal to 45%) in pediatric patients ages 6 months and older.
Age Restrictions	
Prescriber Restrictions	Cardiologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cotellic

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Covered for BRAF+ metastatic melanoma for combination use in with Zelboraf
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cuprimine

Products Affected

- *penicillamine oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	serum ceruloplasmin if used for wilson's disease
Age Restrictions	
Prescriber Restrictions	rheumatology/hepatology/neurology/urology/nephrology
Coverage Duration	12 months
Other Criteria	Coverage for RA requires failure of a TNF-Agent and JAK inhibitor or abatacept.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cyclobenzaprine

Products Affected

- *cyclobenzaprine hcl oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Authorization is required for patients over 64 years of age
Prescriber Restrictions	
Coverage Duration	3 weeks for skeletal muscle spasm, 12 months for fibromyalgia
Other Criteria	For patients over 64 years of age, Physician attests they have counseled patient on risk benefit of muscle relaxers as a high risk medication and patient has been evaluated for fall risk.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Daurismo

Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Diacomit

Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Diagnosis of Dravet syndrome used in combination with clobazam.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Dificid

Products Affected

- DIFICID ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	10 days
Other Criteria	Failure of an adequate treatment of vancomycin and recurrence within 6 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Dronabinol

Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Previous Treatment History
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Infectious disease/oncologist/gastroenterologist
Coverage Duration	12 months
Other Criteria	For HIV/Cancer related cachexia patient must fail megestrol, For Chemotherapy induced nausea, patient must fail Emend and Ondansetron.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Emend

Products Affected

- APREPITANT ORAL CAPSULE
- EMEND ORAL SUSPENSION
RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Previous treatment history
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematologist/oncologist/Surgeon
Coverage Duration	12 months
Other Criteria	Patient must fail treatment with ondansetron (PA not applicable for PONV)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Emgality

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Recent Failure (past 6 months) of two formulary medications with different mechanism of action FDA approved for migraine prophylaxis
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Emsam

Products Affected

- EMSAM

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, current assessment and plan, prior medication failures
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Patient must fail 6 week trial with two formulary anti-depressants
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Enbrel

Products Affected

- ENBREL MINI SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications combination with other biologic
Required Medical Information	Medical notes supporting diagnosis (including imaging, serology when applicable), response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Rheumatology/Dermatology or Specialist trained in management of prescribed condition
Coverage Duration	12 months
Other Criteria	For RA Patient must fail adequate trial(3 month trial in past 6 months) of MTX in combination with a DMARD If MTX contraindicated, must try combination of 2-nonbiologic DMARDS. For Ankylosing Spondylitis PT must fail 2 NSAIDS within past 6 months. For Plaque Psoriasis patient must fail MTX or Soriatane and Topical Therapy(ie. high potency steroids Vit D analogs). For Psoriatic Arthritis Patient must fail adequate trial (3 months in past 6 months) of MTX or LEF in past 6 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

entrectinib (Rozlytrek)

Products Affected

- ROZLYTREK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Rozlytrek is a kinase inhibitor indicated for solid tumors with NTRK-Fusions and ROS-1 mutated Non-Small Cell lung cancer. Medical history, studies, and appropriate confirmatory tests are reviewed in Referrals and if approved will notify pharmacy and the physician.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Epidiolex

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Failure of both Valproate and Clobazam as combination treatment
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Erivedge

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematologist/Oncologist
Coverage Duration	12 months or until progression
Other Criteria	Diagnosis of metastatic basal cell carcinoma OR Diagnosis of locally advanced basal cell carcinoma that has recurred following surgery or when the patient is not a candidate for surgery and radiation
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Erleada

Products Affected

- ERLEADA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Urologist, Oncologist
Coverage Duration	12 months or until PSA progression
Other Criteria	Failure of LHRH agonist and bicalutamide for non-metastatic disease. Failure of abiraterone for metastatic disease.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Esbriet

Products Affected

- *pirfenidone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Confirmed Diagnosis of idiopathic pulmonary fibrosis (IPF) through exclusion of other fibrosing conditions/causes and definitive High resolution CT IPF pattern or Biopsy proven IPF. FVC of at least 50% of predicted value DLCO of at least 30%
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Exjade

Products Affected

- *deferasirox oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	previous treatment history, iron indices
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematologist/oncologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Exkivity

Products Affected

- EXKIVITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	oncology hematology
Coverage Duration	12 months unless disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fanapt

Products Affected

- FANAPT
- FANAPT TITRATION PACK

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Neurology/Psychiatry
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fentanyl Lozenge

Products Affected

- FENTANYL CITRATE BUCCAL LOZENGE ON A HANDLE

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Previous treatment history
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Pain management physician/oncologist
Coverage Duration	12 months
Other Criteria	Covered for breakthrough pain in patients receiving long acting opioid treatment and are opioid tolerant. Patient must fail two immediate release C-II opioid such as hydromorphone, morphine, oxycodone.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fentanyl Patch

Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr*
- *fentanyl transdermal patch 72 hour 12 mcg/hr, 50 mcg/hr, 75 mcg/hr*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Pain management physician/oncologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fetzima

Products Affected

- FETZIMA
- FETZIMA TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Must fail two generically available anti-depressants in past 12 months
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fintepla

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Failure of epidiolex
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Firazyr

Products Affected

- *icatibant acetate subcutaneous solution
prefilled syringe*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fotivda

Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Hematology
Coverage Duration	12 months or until progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fycompa

Products Affected

- FYCOMPA ORAL SUSPENSION
- FYCOMPA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gattex

Products Affected

- GATTEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Gastroenterologist
Coverage Duration	6 months initially
Other Criteria	Diagnosis of Short Bowel Syndrome Dependent on Parenteral Support Baseline Records of parenteral hydration After 6 month trial of Gattex, patient must demonstrate clinical improvement and or reduction in weekly parenteral fluid volume for continuation.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gavreto

Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gilenya

Products Affected

- *fingolimod hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gilotrif

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Hematology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gleostine

Products Affected

- GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	hematology/oncology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Glyburide

Products Affected

- *glyburide micronized*
- *glyburide oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	failure or contraindication to preferred glipizide and glimeperide
Age Restrictions	Prior authorization required for members 65 years or older. Automatic approval for members less than 65 years of age.
Prescriber Restrictions	
Coverage Duration	Through benefit year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Hetlioz

Products Affected

- HETLIOZ
- *tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Confirmed Diagnosis of non-24 hour sleep-Wake disorder Sleep study to rule out Sleep/apnea or other contributory sleep disorders Patient must be totally blind. Covered for microdeletion syndrome Smith-Magenis syndrome.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Humira

Products Affected

- HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PEDIATRIC UC START
- HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML
- HUMIRA PEN-PSOR/UVEIT STARTER
- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications combination with other biologic
Required Medical Information	Medical notes supporting diagnosis (including imaging, serology when applicable), response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Dermatologist/rheumatologist/ Gastroenterologist/Ophthalmologist
Coverage Duration	12 months
Other Criteria	For RA or psoriatic arthritis patient must fail infliximab and a preferred Part D specialty agent either Enbrel, Simponi, r Xeljanz. For Ankylosing spondylitis Patient must fail infiximab and Enbrel or Simponi. For ulcerative colitis patient must fail infliximab and Simponi or Xeljanz. For Crohn's disease patient must fail infliximab and 6-mp. For plaque psoriasis patients must fail infliximab and Enbrel. Part B before Part D Step Therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	Yes

Ibrance

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Iclusig

Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Idhifa

Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Evidence of IDH-1 mutation
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Imbruvica

Products Affected

- IMBRUVICA ORAL CAPSULE
- IMBRUVICA ORAL TABLET 420 MG,
560 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology/ transplant specialist
Coverage Duration	12 months
Other Criteria	Off Label and combination use must be supported by NCCN guidelines with evidence rating of 2a or 1
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Imbruvica Sln

Products Affected

- IMBRUVICA ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology/ transplant specialist
Coverage Duration	12 months
Other Criteria	Unable to swallow or use a tablet or capsule
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Increlex

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Endocrinologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Inlyta

Products Affected

- INLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Inqovi

Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/oncology
Coverage Duration	12 months unless patient has disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Inrebic

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until progression
Other Criteria	Failure of Jakafi
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Invega Sustenna

Products Affected

- INVEGA HAFYERA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Psychiatry or Neurology
Coverage Duration	12 months
Other Criteria	Failure of quetiapine and risperidone
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Iressa

Products Affected

- IRESSA

PA Criteria	Criteria Details
Exclusion Criteria	Iressa is contraindicated in patients with severe hypersensitivity to gefitinib or other components.
Required Medical Information	Diagnosis
Age Restrictions	Patient must be at least 18 years old or older.
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Approved for Non Small Cell Lung Cancer with Egfr exon 19 deletion or Exon 21 substitution.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Isotretinoin

Products Affected

- *isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For cystic, nodular or scarring acne, must be refractory to oral antibiotics and topical retinoids. Trial of combination oral tetracycline and topical retinoid must have been tried in most recent 6 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

IVIG

Products Affected

- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis, immunoglobulin studies
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For ITP must fail corticosteroids and Anti-D immunoglobulin (if indicated). For other indications must meet current LCD criteria for immunoglobulin therapy. Part B before Part D Step Therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	Yes

Jakafi

Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications, Low risk Disease
Required Medical Information	Diagnosis
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematology, oncology, transplant specialist
Coverage Duration	12 months
Other Criteria	Not covered when used in combination with antiproliferative drugs (i.e lenalidomide), or other JAK or tyrosine kinase inhibitors.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Jaypirca

Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Indicated for third line treatment of mantle cell lymphoma after failure of a BTK inhibiting treatment.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Juxtapid

Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months initially, 12 months for continuation
Other Criteria	Clinical confirmation that patient has HoFH and failure of Statin and PCSK-9 therapy. Continuation of Juxtapid after 3 month trial based on LDL reduction while on therapy. If statin intolerant must fail a PCSK-9 inhibitor.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kalydeco

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Genotyping supportive of mutation status in the FDA label
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kerendia

Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with eplerenone or spironolactone
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Patient has CKD with proteinuria and is on maximal doses of an ACE Inhibitor or maximal dose of an ARB if ACE intolerant AND unable to use an SGLT-2 inhibitor.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kevzara

Products Affected

- KEVZARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Coverage is limited to Rheumatoid arthritis. Must fail a preferred specialty agent (Enbrel, Xeljanz, Simponi). Must have clear documentation of moderate to severe rheumatoid arthritis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Kevzara is a injectible Il-6 antagonist indicated for rheumatoid arthritis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kineret

Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications combination with other biologic
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For RA failure of Enbrel and Humira
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kisqali

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Korlym

Products Affected

- KORLYM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	endocrinologist
Coverage Duration	12 months
Other Criteria	Diagnosis of Cushings syndrome , Type 2 diabetes mellitus , Failed surgery OR not a candidate for surgery , Failure of ketoconazole
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Koselugo

Products Affected

- KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	neurology/hematology/oncology
Coverage Duration	12 months
Other Criteria	Diagnosis of Type 1 neurofibromatosis with symptomatic or inoperable plexiform neurofibromas
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Krazati

Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	Progression on another KRAS inhibitor such as sotorasib
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months
Other Criteria	Presence of G12C mutation with metastatic or locally advanced Non-Small Cell Lung Cancer. Patient must not have progressive disease on treatment for continuation of coverage
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kuvan

Products Affected

- *sapropterin dihydrochloride oral packet*
- *sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to dietary changes, current assessment and plan, serum phenylalanine.
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Medical Geneticist, neurologist, hepatologist, Metabolic specialist
Coverage Duration	12 months
Other Criteria	Coverage will be based on medical history/status, response to previous treatments, and the consideration of other therapeutic options
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lenvima

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lidoderm

Products Affected

- *lidocaine external patch 5%*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

liraglutide (Victoza)

Products Affected

- VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Failure of Bydureon for patients without established Cardiovascular disease or multiple cardiovascular risk factors. Covered for multiple cardiovascular risk factors or established cardiovascular disease. Not covered in combination with a DPP-IV inhibitor.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lobrena

Products Affected

- LORBRENA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Evidence of ALK+ mutation
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lokelma

Products Affected

- LOKELMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 month
Other Criteria	Two elevated serum potassium levels in absence of potassium sparing medications.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Long Acting Anti-Psychotics Injections

Products Affected

- ABILIFY MAINTENA
INTRAMUSCULAR PREFILLED SYRINGE
- INVEGA SUSTENNA
INTRAMUSCULAR SUSPENSION
- PREFILLED SYRINGE
- RISPERDAL CONSTA
INTRAMUSCULAR SUSPENSION
RECONSTITUTED ER

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Neurology Psychiatry
Coverage Duration	12 months
Other Criteria	Failure of two generic anti-psychotics in the past 12 months
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lonsurf

Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lotronex

Products Affected

- *alosetron hcl*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Gastroenterologist
Coverage Duration	12 months
Other Criteria	Failure of loperimide and a tricyclic antidepressant. Approved initially for 3 months continuation to 12 months if patient has improvement in symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lumakras

Products Affected

- LUMAKRAS ORAL TABLET 120 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Hematology
Coverage Duration	12 months or until progression
Other Criteria	Submission of molecular profile of tumor supporting KRAS G12C mutation
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lybalvi

Products Affected

- LYBALVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology/Psychiatry
Coverage Duration	12 months
Other Criteria	Failure of Olanzapine and Quetiapine
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lynparza

Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lytgobi

Products Affected

- *lytgobi (12 mg daily dose)*
- *lytgobi (16 mg daily dose)*
- *lytgobi (20 mg daily dose)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/hematology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mavyret

Products Affected

- MAVYRET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Gastroenterology, infectious disease, Hepatology
Coverage Duration	8 weeks to 16 weeks
Other Criteria	Information supporting diagnosis,genotype,and Metavir score.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mekinist

Products Affected

- MEKINIST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or until disease progression
Other Criteria	Mutation analysis showing BRAF V600E or V600K positive, not covered for combination use with other anti-neoplastics unless FDA indication or NCCN recommended with a class 2A or greater evidence rating.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mektovi

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Evidence of BRAF mutation
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Metaxalone

Products Affected

- *metaxalone oral tablet 800 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	4 weeks
Other Criteria	For patients over 64 years of age, Physician attests they have counseled patient on risk benefit of muscle relaxers as a high risk medication and patient has been evaluated for fall risk.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Movantik

Products Affected

- MOVANTIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12months
Other Criteria	Failure of Lactulose and polyethylele glycol 3350 (Miralax)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Myrbetriq

Products Affected

- MYRBETRIQ ORAL TABLET
EXTENDED RELEASE 24 HOUR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Failure of Trospium, solifenacin, or Toviaz
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Natpara

Products Affected

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	iPTH, Calcium
Age Restrictions	
Prescriber Restrictions	endocrinologist
Coverage Duration	12 months
Other Criteria	Hypocalcemia despite using maximal doses of calcitriol
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nerlynx

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematologist/Oncologist
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Neupro

Products Affected

- NEUPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Failure of Ropinirole and Pramipexole
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nexavar

Products Affected

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ninlaro

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Failure of Velcade and Revlimid required for coverage
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Northera

Products Affected

- *droxidopa*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Documented orthostatic hypotension, failure of midodrine or Fludrocortisone. No perquisite drugs required for Dopamine-Beta-Hydroxylase deficiency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Noxafil

Products Affected

- NOXAFIL ORAL SUSPENSION
- *posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	Failure, resistance or contraindication to itraconazole,voriconazole
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nubeqa

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient has failed Xtandi for premetastatic castrate resistant prostate cancer.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or until Disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nucala

Products Affected

- NUCALA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following criteria must be met for coverage for severe eosinophilic asthma: Prescriber must be a pulmonologist or allergist, and patient must fail trial of LABA+ICS combination and a leukotriene receptor antagonist. For Hypereosinophilic syndrome failure of corticosteroids or imatinib and hydroxyurea. For nasal polyps failure of intranasal corticosteroid.
Age Restrictions	
Prescriber Restrictions	Pulmonologist, Allergist, Otolaryngologist, hematologist, or Rheumatologist
Coverage Duration	12 months
Other Criteria	Nucala is an interleukin 5 antagonist covered for indications of eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nuedexta

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis
Age Restrictions	
Prescriber Restrictions	neurology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nuplazid

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology Psychiatry
Coverage Duration	12 months
Other Criteria	Notes supporting dementia with hallucinations or delusions secondary to parkinsons dementia.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nurtec

Products Affected

- NURTEC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology, Pain management, headache specialist
Coverage Duration	12 months
Other Criteria	Failure of eletriptan and sumatriptan for abortive treatment, failure of topiramate and Aimovig for migraine prophylaxis.
Indications	Some FDA-approved Indications Only.
Off Label Uses	
Part B Prerequisite	No

Odomzo

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Approval will initially be for three months, if patient has a response to therapy will be renewed for 12 months
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ofev

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	pulmonologist
Coverage Duration	12 months
Other Criteria	Confirmed Diagnosis of idiopathic pulmonary fibrosis (IPF) through exclusion of other fibrosing conditions/causes and definitive High resolution CT IPF pattern or Biopsy proven IPF. FVC of at least 50% of predicted value DLCO of at least 30%. Confirmed Diagnosis of systemic sclerosis associated interstitial lung disease. Confirmed diagnosis chronic fibrosis interstitial lung diseases and discontinuation of medications which can cause pulmonary fibrosis if risk outweighs benefit.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Omnitrope

Products Affected

- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	studies establishing diagnosis of indication.
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Endocrinologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Onfi

Products Affected

- *clobazam*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis
Age Restrictions	FDA approved Ages
Prescriber Restrictions	Restricted to Neurology
Coverage Duration	12 Months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Onureg

Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Hematology
Coverage Duration	12 months or until progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Opsumit

Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	pulmonologist/cardiologist
Coverage Duration	12 months
Other Criteria	Failure of Ambrisentan and tadalafil
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orenitram

Products Affected

- ORENITRAM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Right Heart catheterization to confirm the diagnosis
Age Restrictions	
Prescriber Restrictions	Pulmonologist or Cardiologist
Coverage Duration	12 months
Other Criteria	Failure of combination Ambrisentan and tadalafil
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

orgovyx

Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Urology/Hematology
Coverage Duration	12 months or until progression
Other Criteria	Failure or intolerance of degaralix and leuprolide
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orilissa

Products Affected

- ORILISSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	OB/GYN
Coverage Duration	6 months
Other Criteria	Covered for endometriosis, failure of NSAID and combinedestrogen-progestin contraceptive or progestin.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orkambi

Products Affected

- ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG
- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CFTR mutation analysis, spirometry
Age Restrictions	Ages approved in FDA label
Prescriber Restrictions	pulmonologist
Coverage Duration	12 months
Other Criteria	CFTR mutation must be supported by FDA approved label such as homozygous F508-deletion
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orserdu

Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Approved for ESR-1 mutated ER+ HER2- advanced or metastatic breast cancer which has progressed on a CDK 4/6 inhibitor.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Otezla

Products Affected

- OTEZLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of active psoriatic arthritis or moderate-to-severe plaque psoriasis or Bechet's disease.
Age Restrictions	
Prescriber Restrictions	Rheumatologist, Dermatologist
Coverage Duration	12 months
Other Criteria	For Plaque Psoriasis patient must Fail Enbrel and Infliximab if there is a contraindication to TNF inhibitors then must fail MTX and acitretin. For Psoriatic Arthritis patient must fail a preferred TNF inhibitor (Enbrel/Simponi/Infliximab) and Xeljanz if contraindication to TNF or Xeljanz, must fail MTX and Leflunomide. Part B before Part D Step Therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	Yes

Pemazyre

Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/oncology
Coverage Duration	12 months or until progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Phenoxybenzamine

Products Affected

- *phenoxybenzamine hcl oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Piqray

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or until progression,
Other Criteria	HR+ ER- with PIK3CA mutation advanced/metastatic breast cancer and failure of endocrine therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Pomalyst

Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	FDA contraindications
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Approve for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Covered for patients with Kaposi sarcoma.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Prevyomis

Products Affected

- PREVYMIS ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	100 days post transplantation
Other Criteria	Patient had an allogeneic hematopoietic stemcell transplant within the last 28 days
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Prolastin-C

Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Prolia

Products Affected

- PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Intolerance or contraindication to injectable bisphosphonate required for coverage of prolia. Part B before Part D Step Therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	Yes

Promacta

Products Affected

- PROMACTA ORAL PACKET 12.5 MG
- PROMACTA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, CBC ,Platelet count less than 50,000/ml for ITP, Platelet count of less than 75,000/ml for HCV
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematologist/oncologist, Hepatologist/gastroenterologist, Infectious Disease
Coverage Duration	12 months
Other Criteria	Chronic ITP Refractory to IVIG, corticosteroids or splenectomy as per FDA approval studies not applicable to HCV related thrombocytopenia
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Pulmozyme

Products Affected

- PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, Spirometry
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Pulmonologist
Coverage Duration	12 months
Other Criteria	For Patients with Cystic Fibrosis who have had recurrent pulmonary infections
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

pyrimethamine (Daraprim)

Products Affected

- *pyrimethamine oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 Months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Qinlock

Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	hematology/oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ravicti

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	hepatologist or metabolic specialist such as an endocrinologist or geneticist
Coverage Duration	12 months
Other Criteria	Clinical Failure of Buphenyl
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rebif

Products Affected

- REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Failure of glatiramer
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Repatha

Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For patients with HoFH, HeFH, or with established atherosclerotic cardiovascular disease and Primary hyperlipidemia who require additional LDL lowering: Failure of rosuvastatin 40mg or Atorvastatin 80 combined with ezetimibe 10mg. Diagnosis of must be HeFH supported by Dutch Lipid Clinic Network criteria. Diagnosis of HOFH must be confirmed by genetic testing. Patients who are intolerant to rosuvastatin/ atorvastatin can use an alternative statin + Ezetimibe 10mg. For statin intolerant patients who required additional LDL lowering and have established cardiovascular disease, HoFH, or HeFH: History of statin intolerance to a hydrophilic statin such as fluvastatin, pravastatin, rosuvastatin in the absence of fibrates or other combinations which can increase risk of myopathy or myalgia when used in combination with a statin.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Retacrit

Products Affected

- RETACRIT INJECTION SOLUTION
10000 UNIT/ML, 10000
UNIT/ML(1ML), 2000 UNIT/ML, 20000
UNIT/ML, 3000 UNIT/ML, 4000
UNIT/ML, 40000 UNIT/ML

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Scr, HGB, T-sat, Ferritin
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Hemoglobin must be within FDA approved ranges for initiation and maintenance. Patient must have adequate iron stores to initiate and continue treatment. ESRD will be covered under Medicare Part B
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Retevmo

Products Affected

- RETEVMO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or disease progression
Other Criteria	Diagnosis of metastatic non-small cell lung cancer or metastatic or advanced medullary thyroid carcinoma with RET alterations
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Revatio

Products Affected

- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, 6 min walk, diffusion studies, Rt Heart Cath
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Pulmonologist/Cardiologist
Coverage Duration	12 months
Other Criteria	Pulmonary hypertension must be diagnosed by heart catheterization ,Evaluation, EKG, diffusion studies, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral ,Coverage will be based on medical history/status, vasoreactivity tests.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Revlimid

Products Affected

- *lenalidomide*
- REVLIMID ORAL CAPSULE 10 MG, 15 MG, 25 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, CBC, Bone Marrow Biopsy, Karyotype
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematologist/oncologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rexulti

Products Affected

- REXULTI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12months
Other Criteria	Failure of aripiprazole and risperidone for schizophrenia or failure of combination SSRI and aripiprazole for major depressive disorder.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rezlidhia

Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Presences of an IDH-1 mutation
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rezurock

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology/Transplant
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rubraca

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Hematology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rydapt

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until progression
Other Criteria	Labs supporting FLT3 mutation if being used for AML, not required for systemic mastocytosis
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sabril

Products Affected

- *vigabatrin*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Neurologist
Coverage Duration	12 months
Other Criteria	Patient must fail treat with adjunctive treatment combination (applies to Refractory Partial Complex only)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Scemblix

Products Affected

- SCEMBLIX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology Hematology
Coverage Duration	12 months unless disease progression
Other Criteria	Failure of ponatinib if T315I mutation present.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Secuado

Products Affected

- SECUADO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Restricted to Neurology/Psychiatry
Coverage Duration	12 months
Other Criteria	Failure of olanzapine and risperidone
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sensipar

Products Affected

- *cinacalcet hcl*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, previous treatment history, associated studies iPTH, calcium, phosphate
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Nephrologist/endocrinologist/oncologist
Coverage Duration	12 months
Other Criteria	For secondary hyperparathyroidism related to CKD, patient must fail active vit-D therapy/phosphate binders. ESRD use is excluded from medicare Part D and this authorization will include a determination of Part D vs Part B coverage based indication
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Signifor

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Endocrinologist
Coverage Duration	12 months
Other Criteria	For Cushings Disease failed or poor surgical candidate for pituitary resection
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Simponi

Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For RA Patient must fail 3 month trial of MTX in combination with a DMARD in past 6 months. If MTX contraindicated, must try combination of 2-nonbiologic DMARDS. For Ankylosing Spondylitis PT must fail 2 NSAIDS within past 6 months. For Psoriatic Arthritis Patient must fail 3 trial of MTX or LEF in past 6 months. For ulcerative colitis patient must fail Azathioprine/6MP in combination with a 5-ASA compound.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Solaraze

Products Affected

- *diclofenac sodium external gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Dermatologist, oncologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Somavert

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Endocrinologist
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sprycel

Products Affected

- SPRYCEL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or until disease progression
Other Criteria	Requires failure of imatinib for low risk CML based on Sokal or Hasford scores.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Stelara

Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	gastroenterologist/rheumatologist/dermatologist
Coverage Duration	12 months
Other Criteria	For Crohns, patient must fail Entyvio and Renflexis. For plaque psoriasis, patient must fail Enbrel and Renflexis. For psoriatic arthritis, patient must fail a preferred TNF (enbrel, simponi, renflexis) and Xeljanz. Part B before Part D Step Therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	Yes

Stivarga

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sutent

Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Symlin

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, HA1c BG
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Endocrinologist, Internist
Coverage Duration	12 months
Other Criteria	Patient BG must be non-controlled on optimal doses of insulin
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sympazan

Products Affected

- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Synarel

Products Affected

- SYNAREL

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis, Notes, Previous treatment history
Age Restrictions	Ages approved in FDA Label
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered after patient fails treatment with Lupron for endometriosis or precocious puberty
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tabrecta

Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Hematology
Coverage Duration	12 months or until progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tafinlar

Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or until disease progression
Other Criteria	Mutation analysis showing BRAF V600E or V600K positive, not covered for combination use with other anti-neoplastics unless FDA indication or NCCN recommended with a class 2A or greater evidence rating.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tagrisso

Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	Coverage requires Diagnosis of Non Small Cell Lung cancer EGFR mutations including T790m, exon 19 deletions. For first line use in patients with exon 21 (L858R) EGFR mutation erlotinib failure may be required if NCCN guidelines support use of either drug based on results of Flaura trial.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Taltz

Products Affected

- TALTZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Notes supporting diagnostic evidence and previous treatment history.
Age Restrictions	
Prescriber Restrictions	Rheumatology, Dermatology
Coverage Duration	12 months
Other Criteria	For Plaque Psoriasis must fail a preferred formulary subcutaneous TNF inhibitor(Enbrel) and IV TNF inhibitor (Renflexis). For Psoriatic Arthritis must fail a preferred TNF agent(Enbrel/Simponi/Renflexis) and JAK inhibitor(Xeljanz).For Ankylosing Spondylitis must fail a preferred formulary subcutaneous TNF inhibitor(Enbrel)and IV TNF inhibitor (Renflexis). For non-radiographic axial spondylarthritis failure of a TNF inhibitor. Part B before Part D Step Therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	Yes

Talzenna

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Evidence of germline BRCA mutation
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tarceva

Products Affected

- *erlotinib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Targretin

Products Affected

- *bexarotene external*
- *bexarotene oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology, dermatology
Coverage Duration	12 months or until disease progression
Other Criteria	Must have failed one prior systemic therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tasigna

Products Affected

- TASIGNA

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Covered for failure or relapse of CML when previously treated with imatinib. Covered for newly diagnosed CML patients who are Philadelphia chromosome +. Will also be covered for intolerance or adverse reaction to imatinib. Combination therapy with other tyrosine kinase inhibitors or MTOR inhibitors for CML is not supported.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tazorac

Products Affected

- *tazarotene external cream*
- *tazarotene external gel*
- TAZORAC EXTERNAL CREAM 0.05 %

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Previous treatment history
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Psoriasis patient must have failed medium to high potency topical corticosteroid, For acne patient must have failed Tretinoin and oral antibiotic
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

tazverik

Products Affected

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Hematology
Coverage Duration	12 months or until progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tecfidara

Products Affected

- *dimethyl fumarate oral*
- *dimethyl fumarate starter pack*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Failure of Gilenya
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tepmetko

Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/oncology
Coverage Duration	12 months or until progression
Other Criteria	Molecular profile to support MET exon 14 skipping mutation
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tetrabenazine

Products Affected

- *tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology or Psychiatry
Coverage Duration	12 months
Other Criteria	For tardive dyskinesia causative drug must be discontinued or tried at a lower dose
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Thalomid

Products Affected

- THALOMID

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematologist/oncologist/infectious disease
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tibsovo

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Evidence of IDH-1 Mutation
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tobi Podhaler

Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Medical notes describing indication for the management of cystic fibrosis patients with <i>Pseudomonas aeruginosa</i> and with forced expiratory volume in 1 second (FEV1) greater than 25% or less than 80%.
Age Restrictions	6 years and older
Prescriber Restrictions	
Coverage Duration	Through benefit year
Other Criteria	Safety and efficacy have not been demonstrated in patients with forced expiratory volume in 1 second (FEV1) less than 25% or greater than 80%, or patients colonized with <i>Burkholderia cepacia</i>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tracleer

Products Affected

- *bosentan*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, right heart catheterization, 6 Minute Walk time
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Pulmonologist or cardiologist
Coverage Duration	12 months
Other Criteria	Pulmonary hypertension must be diagnosed by heart catheterization ,Evaluation, EKG, diffusion studies, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral ,Coverage will be based on medical history/status, vasoreactivity tests, failure of sildenafil. Sildenafil failure does not apply to pediatric patients with congenital or ideopathic PAH
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tretinoin Topical

Products Affected

- *tretinoin external cream*
- *tretinoin external gel 0.01 %, 0.025 %*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications, treatment of photoaging, wrinkles
Required Medical Information	Diagnosis
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Trintellix

Products Affected

- TRINTELLIX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Failure of two generically available anti-depressants within past 6 months
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

TRUSELTIQ

Products Affected

- TRUSELTIQ (100MG DAILY DOSE)
- TRUSELTIQ (125MG DAILY DOSE)
- TRUSELTIQ (50MG DAILY DOSE)
- TRUSELTIQ (75MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months unless disease progression
Other Criteria	Clinical notes and pathology supporting indication and FGFR2 fusion or rearrangement.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tukysa

Products Affected

- TUKYSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	hematology/oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Turalio

Products Affected

- TURALIO ORAL CAPSULE 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/hematology
Coverage Duration	12 months or until disease progression
Other Criteria	Patient is not a surgical candidate and has a Tenosynovial giant cell tumor.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tykerb

Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan associated studies
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Patient is using in combination with capecitabine for HER/NEU + Metastatic breast CA, having failed an anthracycline, Herceptin and a taxane, or Patient must be using in combination with an aromatase inhibitor and have HER/NEU+ HR+ metastatic breast CA
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Tymlos

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications/ cumulative tx more than 24month
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan, BMD, PTH, VITD
Age Restrictions	Late adolescents and Adults only
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Patient must fail or have contraindication to bisphosphonates, Vitamin D (25,OH), PTH must be WNL
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ubrelvy

Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist, Headache Specialist, Pain specialist
Coverage Duration	12 months
Other Criteria	Failure of eletriptan and sumatriptan.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Uceris

Products Affected

- *budesonide er oral tablet extended release*
24 hour

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Gastroenterologist
Coverage Duration	8 weeks
Other Criteria	approved for 8 weeks in patients with active mild-moderate ulcerative colitis who are intolerant or have failed 1-1.5 mg/kg of oral prednisone and mesalamine
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Udenyca

Products Affected

- UDENYCA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Uptravi

Products Affected

- UPTRAVI ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Right heart catheterization supporting diagnosis of PAH
Age Restrictions	
Prescriber Restrictions	Pulmonology or Cardiology
Coverage Duration	12 months
Other Criteria	diagnosis of WHO group 1 PAH, failure of Ambrisentan and tadalafil
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Valchor

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Valtoco

Products Affected

- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE
- VALTOCO 20 MG DOSE
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	History of cluster seizures or acute repetitive seizures.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vascepa

Products Affected

- *icosapent ethyl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Approved for patients on a statin with high cardiovascular risk and elevated triglycerides between 150-499mg/dl. Approved for hypertriglyceridemia after failure of fibrate and omega-3-acid ethyl esters. Approved for statin intolerant patients with high cardiovascular risk and elevated triglycerides between 150-499mg/dl.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Venclexta

Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Verzenio

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or clinical progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vitrakvi

Products Affected

- VITRAKVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Evidence of a NTRK fusion
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vizimpro

Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Evidence of EGFR mutated non-small cell lung cancer
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until Disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vonjo

Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematology, Oncology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Voriconazole

Products Affected

- *voriconazole intravenous*
- *voriconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	Covered when two of the following medications have been tried, unless resistance or contraindication precludes use, Itraconazole, fluconazole, ketoconazole. Exclusions to prerequisite medications are Invasive pulmonary aspergillosis, <i>Scedosporium apiospermum</i> , <i>Fusarium</i>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Votrient

Products Affected

- VOTRIENT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vraylar

Products Affected

- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Psychiatry or Neurology
Coverage Duration	12 months
Other Criteria	Requires failure of aripiprazole and risperidone.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Welireg

Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months unless disease progression
Other Criteria	Clinical information and labs supporting diagnosis
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xalkori

Products Affected

- XALKORI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis, documentation support ALK+ NSLC or ROS1 Positive for NSCLC indication.
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Hematology-oncology
Coverage Duration	6 months
Other Criteria	Continuation will be based on lack of disease progression
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xcopri

Products Affected

- XCOPRI
- XCOPRI (250 MG DAILY DOSE)
ORAL TABLET THERAPY PACK 100
& 150 MG
- XCOPRI (350 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Medication history
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Recent failure (past 6 months) of two generically available medications used to treat partial onset seizures.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xeljanz

Products Affected

- XELJANZ
- XELJANZ XR ORAL TABLET
EXTENDED RELEASE 24 HOUR 11
MG, 22 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Rheumatology/Gastroenterologist
Coverage Duration	12 months
Other Criteria	For Rheumatoid arthritis- 3 month trial of Combination DMARD therapy in past 6 months, For Psoriatic Arthritis Patient must fail 3 month trial of MTX or LEF in past 6 months. For ulcerative colitis patient must fail azathioprine/6MP in combination with a 5-ASA compound.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xermelo

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematologist, Oncologist
Coverage Duration	12 months
Other Criteria	Failure of Sandostatin LAR
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xgeva

Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	oncology/endocrinology
Coverage Duration	12 months
Other Criteria	Failure or contraindication to bisphosphonate for osteolytic cancer indications other than giant cell tumor of the bone.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xifaxin

Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Notes to substantiate diagnosis of Hepatic Encephalopathy or Irritable Bowel Syndrome with Diarrhea
Age Restrictions	
Prescriber Restrictions	Gastroenterology/Hepatology
Coverage Duration	12 months for Hepatic Encephalopathy or Three 14 day courses for IBS-D
Other Criteria	Approve for IBS-D if patient has failed a tricyclic antidepressant and loperamide, approval will be limited to three 14 day treatments. Approval for hepatic encephalopathy is based on failure or intolerance of therapeutic doses of lactulose (30-45ml two to four times daily).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xolair

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan. For asthma please submit RAST, aeroallergens results, IgE values
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Pulmonologist, allergist, dermatologist, otolaryngologist
Coverage Duration	12 months
Other Criteria	For Asthma patient Must Fail Combination LABA/ICS. For chronic ideopathic urticaria failure of hydroxyzine and H-2 antagonist.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xospata

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xpovio

Products Affected

- XPOVIO (100 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 50
MG
- XPOVIO (40 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (40 MG TWICE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (60 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 60
MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncology/Hematology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xtandi

Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months or until disease progression
Other Criteria	Failure of Abiraterone for metastatic prostate cancer
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xyrem

Products Affected

- *sodium oxybate*
- XYREM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Physician Board certified in Sleep Medicine or neurologist
Coverage Duration	12 months
Other Criteria	Failure of Modafanil/Armodafinil and amphetamine/dextroamphetamine or failure of fluoxetine for narcolepsy with cataplexy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zavesca

Products Affected

- *miglustat*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Oncologist/Hematologist, Neurologist, Medical Geneticist, Metabolic Specialist.
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zejula

Products Affected

- ZEJULA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zelboraf

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Oncology
Coverage Duration	3 months
Other Criteria	Authorization for continuation past 90 days will be based on absence of disease progression.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zepatier

Products Affected

- ZEPATIER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Gentotype, Viral Load, Fibroscan/Fibrosure or liver biopsy, RAV NS5A panel
Age Restrictions	
Prescriber Restrictions	Infectious disease, Gastroenterology/Hepatology
Coverage Duration	12 or 16 weeks depending on RAV profile as supported by current AASLD guidelines
Other Criteria	Contraindication to GLECAPREVIR/PIBRENTASVIR
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

zileuton (Zyflo)

Products Affected

- *zileuton er*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Pulmonology
Coverage Duration	12 months
Other Criteria	Uncontrolled Asthma while on maximal doses of long acting bronchodilators and inhaled corticosteroids AND montelukast.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zolinza

Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Medical notes supporting diagnosis, response to previous treatments, current assessment and plan
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Oncologist/hematologist/dermatologist
Coverage Duration	12 months
Other Criteria	Failed minimum of two systemic treatments, one of which must be Targretin, unless contraindicated
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ztalmy

Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurology
Coverage Duration	12 months
Other Criteria	Diagnosis of CDK15 deficiency disorder
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zydelig

Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zykadia

Products Affected

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematology/Oncology
Coverage Duration	12 months or until disease progression
Other Criteria	Restricted to use in ALK+ Non Small Cell Lung Cancer
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zyprexa Injection

Products Affected

- *olanzapine intramuscular*
- ZYPREXA RELPREVV
INTRAMUSCULAR SUSPENSION
RECONSTITUTED 210 MG

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Failure of two generic anti-psychotics in the past 12 months
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zytiga

Products Affected

- *abiraterone acetate oral tablet 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	FDA labeled contraindications
Required Medical Information	Diagnosis
Age Restrictions	Ages approved in FDA labeling
Prescriber Restrictions	Oncology/urology
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Index

ABILIFY MAINTENA	
INTRAMUSCULAR PREFILLED	
SYRINGE	104
<i>abiraterone acetate oral tablet 250 mg</i>	240
ACTIMMUNE	1
ADEMPAS	3
AIMOVIG	5
ALECENSA	6
<i>alosetron hcl</i>	106
ALUNBRIG	8
<i>ambrisentan</i>	9
<i>apomorphine hcl subcutaneous</i>	11
APREPITANT ORAL CAPSULE	47
APTIOM	12
ARCALYST	13
<i>armodafinil</i>	14
AUVELITY	16
AVONEX PEN INTRAMUSCULAR	
AUTO-INJECTOR KIT	17
AVONEX PREFILLED	
INTRAMUSCULAR PREFILLED	
SYRINGE KIT	17
AYVAKIT ORAL TABLET 100 MG,	
200 MG, 25 MG, 300 MG, 50 MG	18
BALVERSA	20
BENLYSTA SUBCUTANEOUS	22
BERINERT	23
BESREMI	24
BETASERON SUBCUTANEOUS KIT	25
<i>bexarotene external</i>	185
<i>bexarotene oral</i>	185
<i>bosentan</i>	195
BOSULIF	26
BRAFTOVI ORAL CAPSULE 75 MG ..	27
BRIVIACT ORAL	28
BRUKINSA	29
<i>budesonide er oral tablet extended release</i>	
<i>24 hour</i>	204
CABOMETYX	30
CALQUENCE	31
CAPLYTA	32
CAPRELSA	33
<i>carglumic acid oral tablet soluble</i>	34
CAYSTON	19
<i>cinacalcet hcl</i>	167
CINRYZE	36
<i>clobazam</i>	132
COMETRIQ (100 MG DAILY DOSE)	
ORAL KIT 80 & 20 MG	37
COMETRIQ (140 MG DAILY DOSE)	
ORAL KIT 3 X 20 MG & 80 MG	37
COMETRIQ (60 MG DAILY DOSE)	37
COPIKTRA	38
CORLANOR ORAL SOLUTION	39
CORLANOR ORAL TABLET	39
COTELLIC	40
<i>cyclobenzaprine hcl oral tablet 10 mg, 5</i>	
<i>mg</i>	42
<i>dalfampridine er</i>	10
DAURISMO ORAL TABLET 100	
MG, 25 MG	43
<i>deferasirox oral tablet soluble</i>	56
DIACOMIT	44
<i>diclofenac sodium external gel 3 %</i>	170
DIFICID ORAL TABLET	45
<i>dimethyl fumarate oral</i>	189
<i>dimethyl fumarate starter pack</i>	189
<i>dronabinol</i>	46
<i>droxidopa</i>	122
EMEND ORAL SUSPENSION	
RECONSTITUTED	47
EMGALITY	48
EMGALITY (300 MG DOSE)	48
EMSAM	49
ENBREL MINI	50
ENBREL SUBCUTANEOUS	
SOLUTION 25 MG/0.5ML	50
ENBREL SUBCUTANEOUS	
SOLUTION PREFILLED SYRINGE ...	50
ENBREL SURECLICK	
SUBCUTANEOUS SOLUTION	
AUTO-INJECTOR	50
EPIDIOLEX	52
ERIVEDGE	53
ERLEADA	54
<i>erlotinib hcl</i>	184
<i>everolimus oral tablet 10 mg, 2.5 mg, 5</i>	
<i>mg, 7.5 mg</i>	4

<i>everolimus oral tablet soluble</i>	4	HUMIRA SUBCUTANEOUS	
EXKIVITY.....	57	PREFILLED SYRINGE KIT 10	
FANAPT.....	58	MG/0.1ML, 20 MG/0.2ML, 40	
FANAPT TITRATION PACK.....	58	MG/0.4ML, 40 MG/0.8ML.....	73
FENTANYL CITRATE BUCCAL		IBRANCE.....	74
LOZENGE ON A HANDLE.....	59	<i>icatibant acetate subcutaneous solution</i>	
<i>fentanyl transdermal patch 72 hour 100</i>		<i>prefilled syringe</i>	63
<i>mcg/hr, 25 mcg/hr</i>	60	ICLUSIG.....	75
<i>fentanyl transdermal patch 72 hour 12</i>		<i>icosapent ethyl</i>	209
<i>mcg/hr, 50 mcg/hr, 75 mcg/hr</i>	60	IDHIFA.....	76
FETZIMA.....	61	IMBRUVICA ORAL CAPSULE.....	77
FETZIMA TITRATION.....	61	IMBRUVICA ORAL SUSPENSION....	78
<i> fingolimod hcl</i>	68	IMBRUVICA ORAL TABLET 420	
FINTEPLA.....	62	MG, 560 MG.....	77
FOTIVDA.....	64	INCRELEX.....	79
FYCOMPA ORAL SUSPENSION.....	65	INLYTA.....	80
FYCOMPA ORAL TABLET.....	65	INQOVI.....	81
GAMMAGARD INJECTION		INREBIC.....	82
SOLUTION 2.5 GM/25ML.....	86	INVEGA HAFYERA.....	83
GAMUNEX-C INJECTION		INVEGA SUSTENNA	
SOLUTION 1 GM/10ML.....	86	INTRAMUSCULAR SUSPENSION	
GATTEX.....	66	PREFILLED SYRINGE.....	104
GAVRETO.....	67	IRESSA.....	84
GILOTRIF.....	69	<i>isotretinoin oral capsule 10 mg, 20 mg, 30</i>	
GLEOSTINE ORAL CAPSULE 10		<i>mg, 40 mg</i>	85
MG, 100 MG, 40 MG.....	70	JAKAFI.....	87
<i>glyburide micronized</i>	71	JAYPIRCA ORAL TABLET 100 MG,	
<i>glyburide oral</i>	71	50 MG.....	88
HETLIOZ.....	72	JUXTAPID ORAL CAPSULE 10 MG,	
HUMIRA PEDIATRIC CROHNS		20 MG, 30 MG, 5 MG.....	89
START SUBCUTANEOUS		KALYDECO.....	90
PREFILLED SYRINGE KIT 80		KERENDIA.....	91
MG/0.8ML, 80 MG/0.8ML &		KEVZARA.....	92
40MG/0.4ML.....	73	KINERET SUBCUTANEOUS	
HUMIRA PEN SUBCUTANEOUS		SOLUTION PREFILLED SYRINGE... 93	
PEN-INJECTOR KIT.....	73	KISQALI (200 MG DOSE).....	94
HUMIRA PEN-CD/UC/HS STARTER	73	KISQALI (400 MG DOSE).....	94
HUMIRA PEN-PEDIATRIC UC		KISQALI (600 MG DOSE).....	94
START.....	73	KISQALI FEMARA (200 MG DOSE)... 94	
HUMIRA PEN-PS/UV/ADOL HS		KISQALI FEMARA (400 MG DOSE)... 94	
START SUBCUTANEOUS PEN-		KISQALI FEMARA (600 MG DOSE)... 94	
INJECTOR KIT 40 MG/0.8ML.....	73	KORLYM.....	95
HUMIRA PEN-PSOR/UEVIT		KOSELUGO.....	96
STARTER.....	73	KRAZATI.....	97
		<i>lapatinib ditosylate</i>	201

<i>lenalidomide</i>	158	OMNITROPE SUBCUTANEOUS	
LENVIMA (10 MG DAILY DOSE).....	99	SOLUTION RECONSTITUTED.....	131
LENVIMA (12 MG DAILY DOSE).....	99	ONUREG.....	133
LENVIMA (14 MG DAILY DOSE).....	99	OPSUMIT.....	134
LENVIMA (18 MG DAILY DOSE).....	99	ORENITRAM.....	135
LENVIMA (20 MG DAILY DOSE).....	99	ORGOVYX.....	136
LENVIMA (24 MG DAILY DOSE).....	99	ORILISSA.....	137
LENVIMA (4 MG DAILY DOSE).....	99	ORKAMBI ORAL PACKET 100-125	
LENVIMA (8 MG DAILY DOSE).....	99	MG, 150-188 MG.....	138
<i>lidocaine external patch 5 %</i>	100	ORKAMBI ORAL TABLET.....	138
LOKELMA.....	103	ORSERDU ORAL TABLET 345 MG,	
LONSURF.....	105	86 MG.....	139
LORBRENA.....	102	OTEZLA.....	140
LUMAKRAS ORAL TABLET 120		PANRETIN.....	7
MG.....	107	PEMAZYRE.....	141
LYBALVI.....	108	<i>penicillamine oral capsule</i>	41
LYNPARZA ORAL TABLET.....	109	<i>phenoxybenzamine hcl oral</i>	142
<i>lytgobi (12 mg daily dose)</i>	110	PIQRAY (200 MG DAILY DOSE).....	143
<i>lytgobi (16 mg daily dose)</i>	110	PIQRAY (250 MG DAILY DOSE).....	143
<i>lytgobi (20 mg daily dose)</i>	110	PIQRAY (300 MG DAILY DOSE).....	143
MAVYRET.....	111	<i>pirfenidone</i>	55
MEKINIST.....	112	POMALYST.....	144
MEKTOVI.....	113	<i>posaconazole oral tablet delayed release</i> ..	123
<i>metaxalone oral tablet 800 mg</i>	114	PREVYMIS ORAL.....	145
<i>miglustat</i>	230	PROLASTIN-C INTRAVENOUS	
<i>modafinil</i>	14	SOLUTION RECONSTITUTED.....	146
MOVANTIK.....	115	PROLIA SUBCUTANEOUS	
MYRBETRIQ ORAL TABLET		SOLUTION PREFILLED SYRINGE..	147
EXTENDED RELEASE 24 HOUR.....	116	PROMACTA ORAL PACKET 12.5	
NATPARA.....	117	MG.....	148
NERLYNX.....	118	PROMACTA ORAL TABLET.....	148
NEUPRO.....	119	PULMOZYME INHALATION	
NINLARO.....	121	SOLUTION 2.5 MG/2.5ML.....	149
NOXAFIL ORAL SUSPENSION.....	123	<i>pyrimethamine oral</i>	150
NUBEQA.....	124	QINLOCK.....	151
NUCALA.....	125	RAVICTI.....	152
NUDEXTA.....	126	REBIF REBIDOSE	
NUPLAZID ORAL CAPSULE.....	127	SUBCUTANEOUS SOLUTION	
NUPLAZID ORAL TABLET 10 MG..	127	AUTO-INJECTOR.....	153
NURTEC.....	128	REBIF REBIDOSE TITRATION	
ODOMZO.....	129	PACK SUBCUTANEOUS	
OFEV.....	130	SOLUTION AUTO-INJECTOR.....	153
<i>olanzapine intramuscular</i>	239	REBIF SUBCUTANEOUS	
OMNITROPE SUBCUTANEOUS		SOLUTION PREFILLED SYRINGE..	153
SOLUTION CARTRIDGE.....	131		

REBIF TITRATION PACK	
SUBCUTANEOUS SOLUTION	
PREFILLED SYRINGE.....	153
REPATHA.....	154
REPATHA PUSHTRONEX SYSTEM	154
REPATHA SURECLICK.....	154
RETACRIT INJECTION SOLUTION	
10000 UNIT/ML, 10000	
UNIT/ML(1ML), 2000 UNIT/ML,	
20000 UNIT/ML, 3000 UNIT/ML, 4000	
UNIT/ML, 40000 UNIT/ML.....	155
RETEVMO.....	156
REVLIMID ORAL CAPSULE 10 MG,	
15 MG, 25 MG, 5 MG.....	158
REXULTI.....	159
REZLIDHIA.....	160
REZUROCK.....	161
RISPERDAL CONSTA	
INTRAMUSCULAR SUSPENSION	
RECONSTITUTED ER.....	104
ROZLYTREK.....	51
RUBRACA.....	162
<i>rufinamide</i>	21
RYDAPT.....	163
<i>sapropterin dihydrochloride oral packet</i>	98
<i>sapropterin dihydrochloride oral tablet</i>	98
SCSEMBLIX.....	165
SECUADO.....	166
SIGNIFOR.....	168
<i>sildenafil citrate oral tablet 20 mg</i>	157
SIMPONI SUBCUTANEOUS	
SOLUTION AUTO-INJECTOR.....	169
SIMPONI SUBCUTANEOUS	
SOLUTION PREFILLED SYRINGE.	169
<i>sodium oxybate</i>	229
SOMAVERT.....	171
<i>sorafenib tosylate</i>	120
SPRYCEL.....	172
STELARA SUBCUTANEOUS	
SOLUTION 45 MG/0.5ML.....	173
STELARA SUBCUTANEOUS	
SOLUTION PREFILLED SYRINGE.	173
STIVARGA.....	174
<i>sunitinib malate</i>	175
SYMLINPEN 120 SUBCUTANEOUS	
SOLUTION PEN-INJECTOR.....	176
SYMLINPEN 60 SUBCUTANEOUS	
SOLUTION PEN-INJECTOR.....	176
SYMPAZAN.....	177
SYNAREL.....	178
TABRECTA.....	179
<i>tadalafil (pah)</i>	2
<i>tadalafil oral tablet 2.5 mg, 5 mg</i>	35
TAFINLAR.....	180
TAGRISSE.....	181
TALTZ.....	182
TALZENNA.....	183
TASIGNA.....	186
<i>tasimelteon</i>	72
<i>tazarotene external cream</i>	187
<i>tazarotene external gel</i>	187
TAZORAC EXTERNAL CREAM 0.05	
%.....	187
TAZVERIK.....	188
TEPMETKO.....	190
<i>teriflunomide</i>	15
<i>tetrabenazine</i>	191
THALOMID.....	192
TIBSOVO.....	193
TOBI PODHALER.....	194
<i>tretinoin external cream</i>	196
<i>tretinoin external gel 0.01 %, 0.025 %</i>	196
TRINTELLIX.....	197
TRUSELTIQ (100MG DAILY DOSE)	198
TRUSELTIQ (125MG DAILY DOSE)	198
TRUSELTIQ (50MG DAILY DOSE)..	198
TRUSELTIQ (75MG DAILY DOSE)..	198
TUKYSA.....	199
TURALIO ORAL CAPSULE 200 MG	200
TYMLOS.....	202
UBRELVY.....	203
UDENYCA.....	205
UPTRAVI ORAL.....	206
VALCHLOR.....	207
VALTOCO 10 MG DOSE.....	208
VALTOCO 15 MG DOSE.....	208
VALTOCO 20 MG DOSE.....	208
VALTOCO 5 MG DOSE.....	208
VENCLEXTA.....	210

VENCLEXTA STARTING PACK.....	210	XPOVIO (80 MG ONCE WEEKLY)	
VERZENIO.....	211	ORAL TABLET THERAPY PACK 40	
VICTOZA SUBCUTANEOUS		MG.....	227
SOLUTION PEN-INJECTOR.....	101	XPOVIO (80 MG TWICE WEEKLY)..	227
<i>vigabatrin</i>	164	XTANDI ORAL CAPSULE.....	228
VITRAKVI.....	212	XTANDI ORAL TABLET 40 MG, 80	
VIZIMPRO.....	213	MG.....	228
VONJO.....	214	XYREM.....	229
<i>voriconazole intravenous</i>	215	ZEJULA.....	231
<i>voriconazole oral</i>	215	ZELBORAF.....	232
VOTRIENT.....	216	ZEPATIER.....	233
VRAYLAR ORAL CAPSULE.....	217	<i>zileuton er</i>	234
VRAYLAR ORAL CAPSULE		ZOLINZA.....	235
THERAPY PACK.....	217	ZTALMY.....	236
WELIREG.....	218	ZYDELIG.....	237
XALKORI.....	219	ZYKADIA ORAL TABLET.....	238
XCOPRI.....	220	ZYPREXA RELPREVV	
XCOPRI (250 MG DAILY DOSE)		INTRAMUSCULAR SUSPENSION	
ORAL TABLET THERAPY PACK		RECONSTITUTED 210 MG.....	239
100 & 150 MG.....	220		
XCOPRI (350 MG DAILY DOSE).....	220		
XELJANZ.....	221		
XELJANZ XR ORAL TABLET			
EXTENDED RELEASE 24 HOUR 11			
MG, 22 MG.....	221		
XERMELO.....	222		
XGEVA.....	223		
XIFAXAN ORAL TABLET 550 MG..	224		
XOLAIR.....	225		
XOSPATA.....	226		
XPOVIO (100 MG ONCE WEEKLY)			
ORAL TABLET THERAPY PACK 50			
MG.....	227		
XPOVIO (40 MG ONCE WEEKLY)			
ORAL TABLET THERAPY PACK 40			
MG.....	227		
XPOVIO (40 MG TWICE WEEKLY)			
ORAL TABLET THERAPY PACK 40			
MG.....	227		
XPOVIO (60 MG ONCE WEEKLY)			
ORAL TABLET THERAPY PACK 60			
MG.....	227		
XPOVIO (60 MG TWICE WEEKLY)..	227		